Literature DB >> 7727782

Mutations of the p53 and ras genes in childhood t(1;19)-acute lymphoblastic leukemia.

M Kawamura1, A Kikuchi, S Kobayashi, R Hanada, K Yamamoto, K Horibe, T Shikano, K Ueda, K Hayashi, T Sekiya.   

Abstract

We have investigated the alterations of p53 and ras genes including H-, K-, and N-ras genes in 22 acute lymphoblastic leukemia (ALL) cases and five cell lines carrying t(1;19) by use of polymerase chain reaction (PCR)-single-strand conformation polymorphism (SSCP) analysis and direct sequencing. The mutations of the p53 gene were found in 2 of 20 t(1;19)-ALL cases at diagnosis (10%), all of 4 cases at relapse (100%), and 4 of the 5 cell lines (80%). Four of the five patients who died had missense mutations at codons 49, 177, 179, and 248. In cases examined sequentially, one had the same point mutation at codon 179 at both diagnosis and relapse, and another had the same p53 gene mutation at codon 240 both in leukemic cells at relapse and in a cell line derived at that time. The other case had no mutation at diagnosis but had the mutation at codon 177 at relapse and cell lines derived from blast cells at diagnosis, suggesting that a small number of leukemic cells with the p53 gene mutation at diagnosis might have escaped PCR-SSCP analysis. In cell lines, SCMC-L9 had three point mutations in the p53 gene at codons 175, 248, and 358, whereas SCMC-L10 had frame shift at codons 209-211. One case had a rare polymorphism at codon 11. We found only one mutation of the N-ras gene that was a 2-bp substitution of GGT(Gly) to GTC(Val) at codon 13 among 22 t(1;19)-ALL cases and five cell lines. This case showed no mutation of the p53 gene and has had a good course. These results suggest that in t(1;19)-ALL, mutations of the p53 and ras genes are infrequent at diagnosis and that p53 gene alterations may be associated with relapse phase or progression of t(1;19)-ALL.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7727782

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  12 in total

1.  The human ZBP-89 homolog, located at chromosome 3q21, represses gastrin gene expression.

Authors:  D J Law; S A Tarlé; J L Merchant
Journal:  Mamm Genome       Date:  1998-02       Impact factor: 2.957

2.  Copy number abnormality of acute lymphoblastic leukemia cell lines based on their genetic subtypes.

Authors:  Chihiro Tomoyasu; Toshihiko Imamura; Toshihiro Tomii; Mio Yano; Daisuke Asai; Hiroaki Goto; Akira Shimada; Masashi Sanada; Shotaro Iwamoto; Junko Takita; Masayoshi Minegishi; Takeshi Inukai; Kanji Sugita; Hajime Hosoi
Journal:  Int J Hematol       Date:  2018-05-21       Impact factor: 2.490

Review 3.  The genotypes and phenotypes of missense mutations in the proline domain of the p53 protein.

Authors:  David Hoyos; Benjamin Greenbaum; Arnold J Levine
Journal:  Cell Death Differ       Date:  2022-04-05       Impact factor: 12.067

4.  Comparative genomics reveals multistep pathogenesis of E2A-PBX1 acute lymphoblastic leukemia.

Authors:  Jesús Duque-Afonso; Jue Feng; Florian Scherer; Chiou-Hong Lin; Stephen H K Wong; Zhong Wang; Masayuki Iwasaki; Michael L Cleary
Journal:  J Clin Invest       Date:  2015-08-24       Impact factor: 14.808

Review 5.  Gene expression profiling in childhood acute leukemia: progress and perspectives.

Authors:  Yasuhide Hayashi
Journal:  Int J Hematol       Date:  2003-12       Impact factor: 2.490

6.  Anti-leukemic activity of bortezomib and carfilzomib on B-cell precursor ALL cell lines.

Authors:  Kazuya Takahashi; Takeshi Inukai; Toshihiko Imamura; Mio Yano; Chihiro Tomoyasu; David M Lucas; Atsushi Nemoto; Hiroki Sato; Meixian Huang; Masako Abe; Keiko Kagami; Tamao Shinohara; Atsushi Watanabe; Shinpei Somazu; Hiroko Oshiro; Koshi Akahane; Kumiko Goi; Jiro Kikuchi; Yusuke Furukawa; Hiroaki Goto; Masayoshi Minegishi; Shotaro Iwamoto; Kanji Sugita
Journal:  PLoS One       Date:  2017-12-13       Impact factor: 3.240

7.  A specific linkage between the incidence of TP53 mutations and type of chromosomal translocations in B-precursor acute lymphoblastic leukemia cell lines.

Authors:  Takeshi Inukai; Xiuru Zhang; Takeshi Kameyama; Yukiko Suzuki; Kazuhito Yoshikawa; Itaru Kuroda; Atsushi Nemoto; Koshi Akahane; Hiroki Sato; Kumiko Goi; Kazunori Nakamoto; Jun-ichi Hamada; Mitsuhiro Tada; Tetsuya Moriuchi; Kanji Sugita
Journal:  Am J Hematol       Date:  2010-07       Impact factor: 10.047

8.  Mutational and functional genetics mapping of chemotherapy resistance mechanisms in relapsed acute lymphoblastic leukemia.

Authors:  Koichi Oshima; Junfei Zhao; Pablo Pérez-Durán; Jessie A Brown; Juan Angel Patiño-Galindo; Timothy Chu; Aidan Quinn; Thomas Gunning; Laura Belver; Alberto Ambesi-Impiombato; Valeria Tosello; Zhengqiang Wang; Maria Luisa Sulis; Motohiro Kato; Katsuyoshi Koh; Maddalena Paganin; Giuseppe Basso; Milagros Balbin; Concepcion Nicolas; Julie M Gastier-Foster; Meenakshi Devidas; Mignon L Loh; Elisabeth Paietta; Martin S Tallman; Jacob M Rowe; Mark Litzow; Mark D Minden; Jules Meijerink; Raul Rabadan; Adolfo Ferrando
Journal:  Nat Cancer       Date:  2020-10-19

Review 9.  Ras/Raf/MEK/ERK Pathway Activation in Childhood Acute Lymphoblastic Leukemia and Its Therapeutic Targeting.

Authors:  Thomas Knight; Julie Anne Elizabeth Irving
Journal:  Front Oncol       Date:  2014-06-24       Impact factor: 6.244

10.  Outcome of TCF3-PBX1 positive pediatric acute lymphoblastic leukemia patients in Japan: a collaborative study of Japan Association of Childhood Leukemia Study (JACLS) and Children's Cancer and Leukemia Study Group (CCLSG).

Authors:  Daisuke Asai; Toshihiko Imamura; Yuka Yamashita; So-ichi Suenobu; Akiko Moriya-Saito; Daiichiro Hasegawa; Takao Deguchi; Yoshiko Hashii; Mikiya Endo; Naoki Hatakeyama; Hirohide Kawasaki; Hiroki Hori; Keizo Horibe; Keiko Yumura-Yagi; Junichi Hara; Arata Watanabe; Atsushi Kikuta; Megumi Oda; Atsushi Sato
Journal:  Cancer Med       Date:  2014-02-28       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.